WallStSmart

American Express Company (AXP)vsBristol-Myers Squibb Company (BMY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

American Express Company generates 42% more annual revenue ($68.81B vs $48.48B). AXP leads profitability with a 16.3% profit margin vs 15.0%. AXP appears more attractively valued with a PEG of 1.55. AXP earns a higher WallStSmart Score of 68/100 (B-).

AXP

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 5.0Quality: 3.5
Piotroski: 4/9Altman Z: 0.13

BMY

Buy

60

out of 100

Grade: C+

Growth: 4.7Profit: 9.0Value: 6.7Quality: 4.5
Piotroski: 6/9Altman Z: 1.42
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AXP.

BMYUndervalued (+32.0%)

Margin of Safety

+32.0%

Fair Value

$88.08

Current Price

$56.16

$31.92 discount

UndervaluedFair: $88.08Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AXP4 strengths · Avg: 9.0/10
Market CapQuality
$217.45B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.4%10/10

Every $100 of equity generates 34 in profit

Operating MarginProfitability
21.2%8/10

Strong operational efficiency at 21.2%

Free Cash FlowQuality
$2.65B8/10

Generating 2.7B in free cash flow

BMY4 strengths · Avg: 9.3/10
Return on EquityProfitability
38.7%10/10

Every $100 of equity generates 39 in profit

Operating MarginProfitability
33.0%10/10

Strong operational efficiency at 33.0%

Market CapQuality
$114.68B9/10

Large-cap with strong market position

P/E RatioValuation
15.7x8/10

Attractively priced relative to earnings

Areas to Watch

AXP3 concerns · Avg: 3.0/10
PEG RatioValuation
1.554/10

Expensive relative to growth rate

Debt/EquityHealth
1.733/10

Elevated debt levels

Altman Z-ScoreHealth
0.132/10

Distress zone — elevated risk

BMY4 concerns · Avg: 2.3/10
Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

PEG RatioValuation
181.372/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.422/10

Distress zone — elevated risk

Debt/EquityHealth
2.551/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : AXP

The strongest argument for AXP centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 16.3% and operating margin at 21.2%. Revenue growth of 11.6% demonstrates continued momentum.

Bull Case : BMY

The strongest argument for BMY centers on Return on Equity, Operating Margin, Market Cap.

Bear Case : AXP

The primary concerns for AXP are PEG Ratio, Debt/Equity, Altman Z-Score. Debt-to-equity of 1.73 is elevated, increasing financial risk.

Bear Case : BMY

The primary concerns for BMY are Revenue Growth, PEG Ratio, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.

Key Dynamics to Monitor

AXP profiles as a mature stock while BMY is a value play — different risk/reward profiles.

AXP carries more volatility with a beta of 1.08 — expect wider price swings.

AXP is growing revenue faster at 11.6% — sustainability is the question.

AXP generates stronger free cash flow (2.7B), providing more financial flexibility.

Bottom Line

AXP scores higher overall (68/100 vs 60/100), backed by strong 16.3% margins and 11.6% revenue growth. BMY offers better value entry with a 32.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

American Express Company

FINANCIAL SERVICES · CREDIT SERVICES · USA

The American Express Company is a multinational financial services corporation headquartered at 200 Vesey Street in the Battery Park City neighborhood of Lower Manhattan in New York City.

Visit Website →

Bristol-Myers Squibb Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.

Visit Website →

Want to dig deeper into these stocks?